Wedbush downgraded Alto Neuroscience (ANRO) to Neutral from Outperform with a price target of $4, down from $29.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANRO:
- Alto Neuroscience downgraded to Neutral from Buy at Rodman & Renshaw
- Alto Neuroscience price target lowered to $10 from $32 at Baird
- Alto Neuroscience CEO says ‘strong cash balance to support us’
- Alto Neuroscience falls 47% after announcing ALTO-100 did not meet endpoint
- Alto Neuroscience’s Phase 2b study of ALTO-100 did not meet primary endpoint